Everolimus and Viekira Pak
Determining the interaction of Everolimus and Viekira Pak and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with potent or moderate inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of everolimus following oral administration. Everolimus is a substrate of both the CYP450 3A4 isoenzyme and P-glycoprotein drug efflux transporter, thus their inhibition in the intestine can enhance the absorption of everolimus. The risk of side effects such as pneumonitis, stomatitis, infection, dyspnea, diarrhea, anemia, leucopenia, thrombocytopenia, hyperglycemia, and hyperlipidemia may be increased. MANAGEMENT: Concomitant use of everolimus with potent or moderate inhibitors of CYP450 3A4 and/or P-glycoprotein should generally be avoided. References "Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals, East Hanover, NJ. Homma S, Takahashi KI, Nihei S, Kato F, Sugihara S, Nunoda S "The successful management of respiratory complications with long-term, low-dose macrolide administration in pediatric heart transplant recipients." Int Heart J (2014):
Professional:GENERALLY AVOID: Coadministration with potent or moderate inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of everolimus following oral administration. Everolimus is a substrate of both the CYP450 3A4 isoenzyme and P-glycoprotein drug efflux transporter, thus their inhibition in the intestine can enhance the absorption of everolimus. The risk of side effects such as pneumonitis, stomatitis, infection, dyspnea, diarrhea, anemia, leucopenia, thrombocytopenia, hyperglycemia, and hyperlipidemia may be increased.
MANAGEMENT: Concomitant use of everolimus with potent or moderate inhibitors of CYP450 3A4 and/or P-glycoprotein should generally be avoided.
- "Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals, East Hanover, NJ.
- Homma S, Takahashi KI, Nihei S, Kato F, Sugihara S, Nunoda S "The successful management of respiratory complications with long-term, low-dose macrolide administration in pediatric heart transplant recipients." Int Heart J (2014):
Generic Name: everolimus
Brand name: Zortress, Afinitor, Afinitor Disperz
Synonyms: n.a.
Generic Name: dasabuvir / ombitasvir / paritaprevir / ritonavir
Brand name: Viekira Pak, Viekira XR
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Everolimus-Viekira XR
- Everolimus-Vienva
- Everolimus-Vigabatrin
- Everolimus-Vigabatrin Oral Solution
- Everolimus-Vigabatrin Tablets
- Everolimus-Vigadrone
- Viekira Pak-Everolimus Tablets (Afinitor)
- Viekira Pak-Everolimus Tablets (Zortress)
- Viekira Pak-Everolimus Tablets For Oral Suspension
- Viekira Pak-Evista
- Viekira Pak-Evoclin
- Viekira Pak-Evoclin Topical